0001104659-22-085738.txt : 20220804 0001104659-22-085738.hdr.sgml : 20220804 20220803183051 ACCESSION NUMBER: 0001104659-22-085738 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220804 DATE AS OF CHANGE: 20220803 EFFECTIVENESS DATE: 20220804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Synthetic Biologics, Inc. CENTRAL INDEX KEY: 0000894158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133808303 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-454779 FILM NUMBER: 221134078 BUSINESS ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (734) 332-7800 MAIL ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ADEONA PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: PIPEX PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20061214 FORMER COMPANY: FORMER CONFORMED NAME: SHEFFIELD PHARMACEUTICALS INC DATE OF NAME CHANGE: 19970730 D 1 primary_doc.xml X0708 D LIVE 0000894158 Synthetic Biologics, Inc. 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD MARYLAND 20850 (301) 417-4364 NEVADA Adeona Pharmaceuticals, Inc. ADEONA PHARMACEUTICALS, INC. PIPEX PHARMACEUTICALS, INC. SHEFFIELD PHARMACEUTICALS INC Corporation true Steven A. Shallcross 9605 Medical Center Drive Suite 270 Rockville MD MARYLAND 20850 Executive Officer Director Jeffrey J. Kraws 9605 Medical Center Drive Suite 270 Rockville MD MARYLAND 20850 Director John Monahan 9605 Medical Center Drive Suite 270 Rockville MD MARYLAND 20850 Director Jeffrey Wolf 9605 Medical Center Drive Suite 270 Rockville MD MARYLAND 20850 Director Biotechnology Decline to Disclose 06b false 2022-07-29 false true true false 3000000 A.G.P./Alliance Global Partners 8361 None None 590 MADISON AVENUE 36TH FLOOR NEW YORK NY NEW YORK 10022 NY NEW YORK false 3000000 3000000 0 false 1 0 175000 true AGP is receiving $175,000 plus out of pocket expenses 0 While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers. false Synthetic Biologics, Inc. /s/ Steven A. Shallcross Steven A. Shallcross Chief Executive Officer and Chief Financial Officer 2022-08-03